Al Tabaa Y, Casasnovas RO, Baillet C, et al. Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group. Blood Adv. 2023;7(14):3735-3738.

doi:10.1182/bloodadvances.2024013536

In the author affiliations on page 3735, the affiliation for author Yassine Al Tabaa (affiliation 1) should read “Scintidoc Nuclear Medicine Center, Clinique Clémentville, Montpellier, France” instead of “Nuclear Medicine Center, Scintidoc, Montpellier, France.”

© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

2024

Al Tabaa Y, Casasnovas RO, Baillet C, et al. Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group. Blood Adv. 2023;7(14):3735-3738.

Cited By

Email alerts

ASH Publications

American Society of Hematology

Al Tabaa Y, Casasnovas RO, Baillet C, et al. Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group. Blood Adv. 2023;7(14):3735-3738.

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only